Insider · CIK 0001566618
Kyle Guse
Files at CNSY (PLUS THERAPEUTICS, INC.). First filing -, latest -.
Kyle Guse files SEC Form 4 as director at CNSY (PLUS THERAPEUTICS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Kyle Guse has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | CNSY PLUS THERAPEUTICS, INC. | MOption exercise Common Stock | +921 | $0.00 | $0 | 1,843 | 12 d ago |
| Oct 1, 2026 | CNSY PLUS THERAPEUTICS, INC. | MOption exercise Restricted Stock Unitsderivative | -921 | $0.00 | $0 | 1,843 | 12 d ago |
| May 14, 2026 | CNSY PLUS THERAPEUTICS, INC. | AGrant or award Restricted Stock Unitsderivative | +3,686 | $0.00 | $0 | 3,686 | May 18, 2026 |
| May 14, 2026 | CNSY PLUS THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +3,686 | $0.00 | $0 | 3,686 | May 18, 2026 |
| Aug 13, 2025 | CNSY PLUS THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +297,794 | $0.00 | $0 | 297,794 | Aug 15, 2025 |
| Aug 13, 2025 | CNSY PLUS THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Aug 15, 2025 |
Questions about Kyle Guse
Answered from the filings on this page, as of the latest one.
Is Kyle Guse buying or selling?
Kyle Guse has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Kyle Guse's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kyle Guse has 0.
Where does Kyle Guse file Form 4?
Kyle Guse has filed Form 4 at CNSY (PLUS THERAPEUTICS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.